uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
Show others and affiliations
2013 (English)In: European Journal of Clinical Pharmacology, ISSN 0031-6970, E-ISSN 1432-1041, Vol. 69, no 8, 1543-1551 p.Article in journal (Refereed) Published
Abstract [en]

To build a population pharmacokinetic (PK) model of cyclophosphamide (CY) and its metabolite, 4-hydroxycyclophosphamide (HCY), in patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) and to identify covariates, including genetic polymorphisms, which affect CY and HCY PK parameters. The study cohort comprised 21 patients undergoing HSCT who received CY intravenously between 2009 and 2011. Clinical characteristics and CY and HCY concentration data were collected for all patients, and ABCB1, ABCC2, GSTA1, GSTM1, GSTP1, GSTT1, CYP2B6, CYP2C19, and CYP3A5 genotyping was performed. A hypothetical enzyme compartment was conducted using the NONMEM program. A population PK analysis showed that the ABCC2 1249 genotype and aspartate aminotransferase levels significantly affected non-induced clearance (CL (UI)) and induced clearance (CL (I)) of CY, respectively. The final estimate of the mean CL (UI) and CL (I) of CY was 15.5 and 0.683 L/h, respectively, and the mean volume of distribution (V (1)) of CY was 88.0 L. The inter-individual variability for CL (UI), CL (I), and V (1) of CY was 52.8, 200, and 18.0 %, respectively. Additionally, the CL (UI) of CY was significantly decreased to approximately 51 % in patients with the 1249 GA heterozygous genotype compared to those with the 1249 GG wild-type genotype (p < 0.05). There were only three heterozygous GA variants of ABCC2 1249 in the study patients. The population PK model developed in this study implies an influence of genetic factors on the clearance of CY. Clearance was moderately reduced in patients with the ABCC2 1249GA heterozygous genotype.

Place, publisher, year, edition, pages
2013. Vol. 69, no 8, 1543-1551 p.
Keyword [en]
Cyclophosphamide, 4-hydroxycyclophosphamide, Population pharmacokinetics, Pharmacogenetics, Hematopoietic stem cell transplantation
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-206430DOI: 10.1007/s00228-013-1507-7ISI: 000321777700005OAI: oai:DiVA.org:uu-206430DiVA: diva2:645701
Available from: 2013-09-05 Created: 2013-08-30 Last updated: 2013-09-05Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Yun, Hwi-yeol
By organisation
Department of Pharmaceutical Biosciences
In the same journal
European Journal of Clinical Pharmacology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 196 hits
ReferencesLink to record
Permanent link

Direct link